Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells by Happold, C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Interferon-￿ induces loss of spherogenicity and overcomes therapy resistance
of glioblastoma stem cells
Happold, C; Roth, P; Silginer, M; Florea, A M; Lamszus, K; Frei, K; Deenen, R; Reifenberger, G;
Weller, M
Abstract: Glioblastoma is the most common malignant brain tumor in adults and characterized by a
poor prognosis. Glioma cells expressing O(6)-methylguanine DNA methyltransferase (MGMT) exhibit
a higher level of resistance toward alkylating agents, including the standard of care chemotherapeutic
agent temozolomide. Here, we demonstrate that long-term glioma cell lines (LTL) as well as glioma-
initiating cell lines (GIC) express receptors for the immune modulatory cytokine IFN-￿ and respond to
IFN-￿ with induction of STAT-3 phosphorylation. Exposure to IFN-￿ induces a minor loss of viability, but
strongly interferes with sphere formation in GIC cultures. Furthermore, IFN-￿ sensitizes LTL and GIC
to temozolomide and irradiation. RNA interference confirmed that both IFN-￿ receptors, R1 and R2, are
required for IFN-￿-mediated sensitization, but that sensitization is independent of MGMT or TP53. Most
GIC lines are highly temozolomide-resistant, mediated by MGMT expression, but nevertheless susceptible
to IFN-￿ sensitization. Gene expression profiling following IFN-￿ treatment revealed strong upregulation
of IFN-￿-associated genes, including a proapoptotic gene cluster, but did not alter stemness-associated
expression signatures. Caspase activity and inhibition studies revealed the proapoptotic genes to mediate
glioma cell sensitization to exogenous death ligands by IFN-￿, but not to temozolomide or irradiation,
indicating distinct pathways of death sensitization mediated by IFN-￿. Thus, IFN-￿ is a potential adjunct
to glioblastoma treatment that may target the GIC population. IFN-￿ operates independently of MGMT-
mediated resistance, classical apoptosis-regulatory networks, and stemness-associated gene clusters. Mol
Cancer Ther; 13(4); 948-61. ©2014 AACR.
DOI: 10.1158/1535-7163.MCT-13-0772
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-95406
Accepted Version
Originally published at:
Happold, C; Roth, P; Silginer, M; Florea, A M; Lamszus, K; Frei, K; Deenen, R; Reifenberger, G; Weller,
M (2014). Interferon-￿ induces loss of spherogenicity and overcomes therapy resistance of glioblastoma
stem cells. Molecular Cancer Therapeutics, 13(4):948-961. DOI: 10.1158/1535-7163.MCT-13-0772
1 
 
Interferon-β induces loss of spherogenicity and overcomes therapy resistance 
of glioblastoma stem cells 
 
Caroline Happold1, Patrick Roth1, Manuela Silginer1, Ana-Maria Florea4, Katrin 
Lamszus3, Karl Frei2, Rene Deenen4, Guido Reifenberger4,5, Michael Weller1 
 
1Laboratory of Molecular Neuro-Oncology, Department of Neurology, and 
2Department of Neurosurgery, University Hospital Zurich, Frauenklinikstrasse 26, and 
Neuroscience Center Zurich, 8091 Zurich, Switzerland; 3Laboratory for Brain Tumor 
Biology, Department of Neurosurgery, University Hospital Hamburg-Eppendorf, 
Martinistrasse 52, 20246 Hamburg, Germany; 4Department of Neuropathology (A.F., 
G.R.) and Center for Biological and Medical Research (R.D.), Heinrich Heine 
University, Düsseldorf, Germany, 5German Cancer Consortium (DKTK), German 
Cancer Research Center (DKFZ), Heidelberg, Germany 
 
*Correspondence: Prof. Michael Weller, Department of Neurology, University 
Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland, Tel.: +41 (0)44 
255 5500, Fax: +41 (0)44 255 4507, E-mail: Michael.Weller@usz.ch 
 
Running title: Anti-glioma activity of interferon-β 
 
Keywords: glioma, interferon, MGMT, stem cell, temozolomide, irradiation 
 
This work was supported by a grant from the Swiss National Science Foundation 
(31003A_130122) to M.Weller. 
2 
 
Abbreviations 
CNPase, 2', 3'-cyclic nucleotide 3'-phosphodiesterase; DMSO, dimethylsulfoxide; 
EGF, epidermal growth factor; FGF, fibroblast growth factor; FCS, fetal calf serum; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFAP, glial fibrillary acidic 
protein; GIC, glioma-initiating cells; GO, gene ontology; IFN, interferon; IFNAR, 
interferon receptor; IL, interleukin; JAK, Janus kinase; LTL, long-term cell line; MFL, 
Mega-FAS-ligand; MGMT, O6-methylguanine DNA methyltransferase; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered 
saline; PI, propidium iodide; RMA, robust multi-array analysis; RT-PCR, reverse 
transcriptase PCR; SFI, specific fluorescence intensity; sh, small hairpin; si, small 
interfering; STAT, Signal Transducers and Activators of Transcription; STRING, 
Search Tool for the Retrieval of Interacting Genes/Proteins; STS, staurosporine; 
TMZ, temozolomide; TP53, tumor protein p53; TNFSF10/TRAIL, tumor necrosis 
factor-related apoptosis-inducing ligand; XAF-1, XIAP-associated factor 1; XIAP, X-
linked inhibitor of apoptosis 
 
 
 
 
 
 
 
 
 
 
 
3 
 
ABSTRACT  
 
Glioblastoma is the most common malignant brain tumor in adults and characterized 
by a poor prognosis. Glioma cells expressing O6-methylguanine DNA 
methyltransferase (MGMT) exhibit a higher level of resistance towards alkylating 
agents, including the standard of care chemotherapeutic agent, temozolomide (TMZ). 
Here, we demonstrate that long-term glioma cell lines (LTL) as well as glioma-
initiating cell lines (GIC) express receptors for the immune modulatory cytokine 
interferon (IFN)-β and respond to IFN-β with induction of STAT-3 phosphorylation. 
Exposure to IFN-β induces a minor loss of viability, but strongly interferes with sphere 
formation in GIC cultures. Further, IFN-β sensitizes LTL and GIC to TMZ and 
irradiation. RNA interference confirmed that both IFN-β receptors, R1 and R2, are 
required for IFN-β-mediated sensitization, but that sensitization is independent of 
MGMT or TP53. Most GIC lines are highly TMZ-resistant mediated by MGMT 
expression, but nevertheless susceptible to IFN-β sensitization. Gene expression 
profiling following IFN-β treatment revealed strong up-regulation of IFN-β-associated 
genes including a proapoptotic gene cluster, but did not alter stemness-associated 
expression signatures. Caspase activity and inhibition studies revealed the 
proapoptotic genes to mediate glioma cell sensitization to exogenous death ligands 
by IFN-β, but not to TMZ or irradiation, indicating distinct pathways of death 
sensitization mediated by IFN-β. Thus, IFN-β is a potential adjunct to glioblastoma 
treatment that may target the GIC population. IFN-β operates independently of 
MGMT-mediated resistance, classical apoptosis-regulatory networks and stemness-
associated gene clusters. 
 
4 
 
INTRODUCTION 
 
Glioblastomas are characterized by infiltrative growth and resistance to cell death 
induction. Despite multimodal therapy, tumor progression occurs inevitably, and 
survival remains in the range of months (1-3). Early therapy failure is associated with 
the expression of O6-methylguanine-DNA-methyltransferase (MGMT), a DNA repair 
protein that accounts for glioma cell resistance by counteracting the effects of 
alkylating chemotherapy (4). MGMT has become an important molecular marker and 
is now implemented in clinical diagnostics as predictive biomarker for benefit from 
alkylating chemotherapy and clinical outcome (5-7). Patients with a non-methylated 
MGMT promoter are prone to therapy failure with standard alkylating chemotherapy, 
and to date, effective approaches for this large group of patients, comprising more 
than half of all glioblastoma patients, are still lacking, including dose intensification of 
TMZ (8).  
Recently, a subfraction of glioma cells exhibiting stem cell-like properties (stem-like 
glioma cells), referred to as glioma-initiating cells (GIC), has been identified (9, 10). 
GIC are thought to have the ability of self-renewal, tumor initiation and pluripotency, 
and have been proposed to account for the ultimately lethal nature of glioblastoma. 
They may contribute to therapy resistance in vivo and therefore promote tumor 
progression. The value of GIC cultures and their MGMT status as a model to study 
resistance to TMZ in glioblastoma has remained controversial. Among a panel of 20 
GIC lines, some were sensitive to TMZ, which was associated with low MGMT 
protein levels, but not MGMT promoter methylation, and the MGMT promoter status 
was thus not strongly predictive of response to TMZ (11). High TMZ sensitivity of GIC 
cultures lacking MGMT expression has been described in vitro (12). Finally, the 
frequency of MGMT promoter-methylated alleles in glioblastomas may range from 
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10% to 90%, but methylated alleles were enriched in GIC cultures (13). Considering 
the limited activity of current standards of care, new approaches should take into 
account this novel target cell population.  
IFN-β, a member of the interferon class I family, exerts numerous functions for 
cellular differentiation, cell growth and immune responses. IFN-β signaling is 
mediated through binding to a type II cytokine receptor, involving heterodimerization 
of 2 IFN-α/β receptor subunits, IFNAR-1 and IFNAR-2. Down-stream signalling 
pathways involve the Janus kinase/signal Transducers and Activators of 
Transcription (JAK/STAT) pathway (14) and lead to accumulation of MxA protein, a 
GTPase interfering with the cytoskeletal structure (15, 16). MxA induction is an 
established marker for responsiveness to IFN-α/β (17, 18). 
IFN-β has gained great clinical impact in the treatment of multiple sclerosis. Its safety 
profile in patients with brain disease has therefore been firmly established. Moreover, 
IFN-α/β were the first agents to show a significant survival benefit in randomized 
trials in malignant melanoma (19). The mechanisms mediating antitumor effects of 
IFN may involve direct cytostatic, anti-angiogenic or immune modulatory activities. 
IFN-β has been reported to sensitize human glioma cell lines to TMZ in a TP53- and 
MGMT-dependent manner (20, 21). These reports, however, were based on findings 
in T98G and U251MG, both being TP53 mutant cell lines (22, 23). Moreover, IFN-β 
has been attributed anti-stem cell properties in glioma models (24). Finally, clinical 
trials exploring the addition of IFN-β to radiotherapy plus TMZ have been initiated and 
interpreted as promising (25, 26). These data prompted us to evaluate the potential 
role of IFN-β as a component of future, innovative treatment approaches for 
glioblastoma in more detail. In brief, we demonstrate profound anti-GIC activity of 
IFN-β as well as IFN-β-mediated sensitization to TMZ and irradiation, but exclude 
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MGMT and TP53 as primary mediators of these effects. IFN-β exposure induces 
characteristic IFN-β-associated gene clusters, but does not alter the stemness 
signature of GIC. A proapoptotic gene signature induced by IFN-β is functionally 
relevant, but mediates neither anti-GIC properties nor sensitivity to TMZ or 
radiotherapy. 
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MATERIALS AND METHODS 
 
Materials and cell lines 
The human U87MG and T98G glioma cell lines, K562 leukemia cells and MCF-7 
breast adenocarcinoma cells were purchased from the American Type Culture 
Collection (Rockville, MD, USA). The other long-term cell lines (LTL) were kindly 
provided by N. de Tribolet (Lausanne, Switzerland). LNT-229 cells cultured in our 
laboratory express TP53 wild-type transcriptional activity (23). The generation of 
LNT-229 cells depleted of TP or overexpressing MGMT has been described (23, 27). 
MGMT-silenced LN-18 cells were generated by transfection with pSUPER puro 
encoding MGMT short hairpin (sh) RNA using Metafectene Pro transfection reagent 
(Biontex Laboratories GmbH, Martinsried, Germany) (28). The GIC cell lines GS-2, 
GS-5, GS-7, GS-8 and GS-9 have been characterized elsewhere (29). LTL were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf 
serum (FCS), 2 mM glutamine and penicillin (100 IU/ml) / streptomycin (100 µg/ml). 
GS sphere cultures were maintained in Neurobasal Medium® supplemented with 2% 
B-27 supplement, 1% GlutaMAX, 20 ng/ml epidermal growth factor, 20 ng/ml 
fibroblast growth factor and 32 IE/ml heparin. K-562 cells were maintained in RPMI-
1640 supplemented with 1 mmol/L sodium pyruvate (Gibco Life Technologies) and 
10% fetal calf serum. TMZ was provided by Schering-Plough (Kenilworth, NJ, USA). 
A stock solution of TMZ at 200 mM was prepared in dimethylsulfoxide (DMSO). 
Recombinant IFN-β1b was purchased from AbD Serotec (Dusseldorf, Germany), 
reconstituted to a concentration of 1,000,000 IU/ml with distilled water. The following 
antibodies were used: STAT-3 and phospho-STAT-3, Caspase-3 and LC3A/B from 
Cell Signaling (Boston, MA, USA); glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) from Everest Biotech (Oxfordshire, UK); tumor necrosis factor-related 
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apoptosis inducing ligand (TRAIL) and XIAP-associated factor 1 (XAF-1) from Santa 
Cruz (Santa Cruz, CA, USA); caspase 8 from Enzo Life Science (Framingdale, NY, 
USA); Glial fibrillary acidic protein (GFAP) from Dako (Carpinteria, CA, USA); Nestin 
from Zytomed Systems GmbH (Berlin, Germany); β-III tubulin from Abcam 
(Cambridge, UK). Mega-Fas-ligand (MFL) was provided by Topotarget (Copenhagen, 
Denmark). The MxA antibody was kindly provided by O. Haller, MD and G. Kochs, 
PhD (Department of Virology, University of Freiburg, Germany). All other reagents, 
including anti- 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) antibody, O6-
benzylguanine (O6-BG) and salinomycin, were purchased from Sigma (St. Louis, MO, 
USA). For irradiation experiments, cells were irradiated in a Co-radiation source 
(Gebrüder Sulzer, Thermische Energiesysteme, 60-Co, Winterthur, Switzerland) at 1, 
3 and 5 Gy at 24 h after IFN-β exposure. 
 
Polymerase chain reaction 
Total RNA was prepared using the NucleoSpin System (Macherey-Nagel AG, 
Önsingen SO, Switzerland) and transcribed using random primers (Bioconcept/NEB, 
Bioconcept, Allschwil, Switzerland) and Superscript II reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA). For reverse transcriptase PCR, the conditions were: 
35 cycles, 94°C/45 sec, specific annealing temperature (54°C for IFNAR-1, 52°C for 
IFNAR-2, 51°C for GAPDH) /45 sec, 72°C/1 min. For real-time (quantitative) RT-
PCR, cDNA amplification was monitored using SYBRGreen chemistry on the 7300 
Real time PCR System (Applied Biosystems, Zug, Switzerland). The conditions were: 
40 cycles, 95°C/15 sec, 60°C/1 min. Data analysis was done using the ΔΔCT method 
for relative quantification. The following specific primers were used: GAPDH fwd: 5'-
CTCTCTGCTCCTCCTGTTCGAC-3', GAPDH rv: 5'-TGAGCGATGTGGCTCGGCT-
3'; IFNAR-1 fwd: 5'-TAT GCT GCG AAA GTC TTC TTG AG-3’; IFNAR-1 rv: 5'-TCT 
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TGG CTA GTT TGG GAA CTG TA-3’; IFNAR-2 fwd: 5'-TCT TGA GGC AAG GTC 
TCG CTA-3’; IFNAR-2 rv: 5'-CAG GGA TGC ACG CTT GTA ATC-3’; XAF1 fwd: 5’-
AGC AGG TTG GGT GTA CGA TG-3’; XAF1 rv: 5’-TGA GCT GCA TGT CCA GTT 
TG-3’; TRAIL fwd: 5’-TGC GTG CTG ATC GTG ATC TTC-3’ ; TRAIL rv: 5’-GCT CGT 
TGG TAA AGT ACA CGT A-3’. 
 
Flow cytometry, cell cycle and viability assays 
Differentiated glioma cells and sphere cultures were detached respectively 
dissociated using Accutase (PAA Laboratories, Pasching, Austria) and blocked with 
2% FCS in phosphate-buffered saline (PBS). The cells were incubated for 30 min on 
ice using the following PE-labeled antibodies: anti–IFNAR-1 or anti-IFNAR-2 
antibodies (PBL interferon source, Piscataway, NJ, USA) for IFNAR experiments and 
anti-CD133/2-PE (Miltenyi Biotec, Bergisch Gladbach, Germany) for stem cell marker 
experiments. Flow cytometry was performed with a CyAn® flow cytometer (Beckman 
Coulter, Nyon, Switzerland). Signal intensity was calculated as the ratio of the mean 
fluorescence of the specific antibody and the isotype control antibody (specific 
fluorescence index). Dead cells were gated out. For some analyses, cells were 
permeabilized by Fix/Perm Buffer Set (Lucerna Chem AG, Biolegend, Luzern, 
Switzerland). For analysis of cell death, cells were grown in six-well plates, incubated 
with IFN-β at 150 IU/ml for 24 h, washed in PBS and allowed to grow for 48 h. 
Annexin (Anx) V-fluorescein isothiocyanate (1:100) and propidium iodide (PI) (50 
µg/ml) were added, and fluorescence in a total of 10,000 events (cells) per condition 
was recorded in a CyAn flow cytometer. AnxV- or PI-positive cells were counted as 
dead cells, the remaining cells were designated the surviving cell fraction. In some 
experiments, loss of viability was also confirmed by trypan blue dye exclusion. 
Autophagic cell death was assessed by immunoblot and immunostaining. In brief, for 
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the latter, the cells were exposed to IFN-β as indicated and Cytospin samples were 
prepared, fixed in 4% PFA, blocked in TBS containing 0.2% Triton X100, 5% goat 
serum and 5% horse serum, and exposed to the primary LC3A/B antibody (Cell 
Signaling, Boston, MA, USA) overnight at 4°C and 1 h at room temperature for 
secondary antibodies.  
 
Clonogenicity assays 
For LTL, clonogenicity assays were performed by seeding 100 cells (LNT-229, LN-
18) per well in 96-well plates, allowed to adhere overnight, and exposed to IFN-β at 
150 IU/ml for 24 h in fresh medium. After removal of IFN-β, the cells were exposed to 
TMZ at the indicated concentrations for 24 h in serum-free medium, followed by an 
agent-free observation period for 7-14 days in serum-containing medium. Cell density 
was assessed by crystal violet staining. For sphere cultures, the cells were seeded at 
500 cells per well in neurobasal medium and treated consecutively as indicated 
above in neurobasal medium. Lower cell numbers resulted in inefficient sphere 
formation. Cell growth was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Initially, we confirmed that crystal violet 
assay and MTT assay were good surrogate markers of the number of colonies 
respectively spheres in these assays, but easier to standardize for large scale 
concentration response analyses. 
 
Immunoblot analysis  
The cells were treated as indicated and lysed in lysis buffer containing 50 mM Tris-
HCl, 120 mM NaCl, 5 mM EDTA and 0.5% NP-40. Protein (20 µg/lane) was 
separated on 10% acrylamide gels. After transfer to nitrocellulose (Biorad, Munich, 
Germany), the blots were blocked in Tris-buffered saline containing 5% skim milk and 
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0.05% Tween 20 and incubated overnight at 4°C with primary antibodies and 1 h at 
room temperature for secondary antibodies. Visualization of protein bands was 
accomplished using horseradish peroxidase-coupled secondary antibodies (Santa 
Cruz Healthcare, Santa Cruz, CA, USA) and enhanced chemiluminescence (Pierce / 
Thermo Fisher, Madison, WI, USA).  
 
Immunocytochemistry and immunofluorescence microscopy 
For stemness experiments, the cells were exposed to IFN-β (150 IU/ml) for 48 h and 
cytospin samples were prepared, fixed in 4% PFA and blocked in either blocking 
solution (Candor Bioscience GmbH, Wangen, Germany) for GFAP, β-III tubulin or 
CNPase, or PBS containing 10% swine serum and 0.3% Triton X for nestin, and 
exposed to the primary antibody overnight at 4°C and 30 min at room temperature for 
secondary antibodies. Detection was performed with DAB detection systems (Dako) 
for 5 min at room temperature, and slides were mounted in Eukitt (Sigma-Aldrich). 
Counterstaining was performed with hemalum. For IFNAR receptor staining, cytospin 
samples of LTL or GIC were prepared as described above. Staining was performed 
as suggested by the manufacturer, using IFNAR-1 antibody from antibodies-
online.com (Atlanta, GA, USA) and IFNAR-2 antibody from Abcam (Cambridge, UK). 
 
RNA interference-mediated gene silencing 
For transient transfections, 2.5 × 105 glioma cells were seeded in a six-well plate and 
transfected with 100 nM of specific or scrambled control small interfering (si) RNA, 
using Metafectene Transfection reagent (Biontex). siRNA was purchased from 
Dharmacon / Thermo Fisher (Chicago, IL, USA) using siGENOME SMARTpool 
targeting human IFNAR-1 and human IFNAR-2. Samples were collected 48 h post 
transfection and processed for further treatment. 
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Reporter assay 
Dual luciferase/renilla assays were carried out with co-transfection of 150 ng of the 
specific reporter construct and 20 ng of the renilla reniformis-CMV (pRL-CMV) control 
plasmid (Promega, Madison, WI, USA). Luciferase activity was normalized to 
constitutive renilla activity. The pGL2-Luc MGMT construct (30) was a kind gift from 
Dr. S. Mitra (Sealy Center for Molecular Science and Department of Human 
Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, 
TX, USA). The TP53-Luc construct has been described elsewhere (31). 
 
Caspase activity assay  
Cells were seeded at a density of 1000 cells/well in a six-well-plate and treated as 
described above with either IFN-β and TMZ alone or in combination with or without 
ZVAD-fmk, with either MFL (Mega-FAS-ligand) or staurosporine as positive control.  
Cells were incubated in lysis buffer (25 mM Tris/HCL, 60 mM NaCl, 2.5 mM EDTA, 
0.25% NP40) for 10 min, and the substrate Ac-DEVD-amc was added at a 
concentration of 20 µM. Fluorescence was assessed at 360 nm wavelength every 15 
min until extinction of fluorescence (32). 
 
Microarray-based gene expression profiling 
Technical details are provided in the supplementary methods. Array records are 
deposited under GEO accession number GSE53213. 
 
Data analysis  
Data are representative of experiments performed three times with similar results. 
Where indicated, analysis of significance was performed using the two-tailed 
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Student’s t-test. Synergy of irradiation or TMZ and IFN-β was assessed by the 
fractional product method (33) where indicated and differences of 10% of observed 
versus predicted (additive) effect were considered synergistic. For the analysis of 
functional gene interactions, the Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING) Version 9.05 at http://string-db.org (34) was used. Highest 
confidence settings were applied, integrating combined scores higher than 0.900. 
Cluster analysis was performed by application of the Markov Cluster algorithm 
(MCL). Disconnected nodes were hidden from the image.  
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RESULTS 
 
IFNAR are expressed in human glioma cells 
In total, 12 LTL and 5 GIC were assessed for mRNA expression of IFNAR-1 and -2 
by RT-PCR. All lines expressed transcripts for both receptor subunits (Fig. 1A). 
IFNAR-1, in contrast to IFNAR-2, was not detected at the surface on any glioma cell 
line by flow cytometry (Fig. 1B, left panel), but was detected by immunostaining (Fig. 
1B, right panel). Permeabilization of the cells or scraping of cells instead of using 
accutase did not produce a specific signal for IFNAR-1 on flow cytometry either. 
Specific fluorescence intensity (SFI) values for IFNAR-2 above 3 were never seen in 
GIC, but in all LTL (data not shown). 
 
IFN-β signalling in glioma cells involves MxA and STAT-3 
To ensure that IFN-β induces classical signalling pathways in glioma cells, we 
investigated whether STAT-3, the proposed signal transducer in response to IFN-β in 
gliomas, and the IFN-α/β-regulated protein MxA, a classical marker for cellular 
responsiveness to IFN-β, were induced. Immunoblot confirmed that STAT-3 
phosphorylation levels increased shortly after exposure to IFN-β, with a peak at 30-
60 min, with no relevant concentration dependency between 50 and 500 IU/ml, in 
LTL and GIC (Fig. 1C). Likewise, the exposure to IFN-β led to a concentration-
dependent increase of MxA protein in LNT-229 (Fig. 1D, upper row) or LN-18 cells 
(data not shown), in a time-dependent manner (Fig. 1D, lower row), with first marked 
elevation of protein levels at a concentration of 150 IU/ml at 24 h.  
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IFN-β induces cell cycle arrest in glioma cells and causes sphere disruption in 
GIC 
Within the concentration and time ranges of our experiments, IFN-β induced a 
reduction of G1 cells in all cell lines, associated with increases in S cells or G2/M cells 
or both. Moreover, there was an increase in sub-G1 cells indicating minor cell death 
induction (Fig. 2A). A moderate induction of necrotic rather than apoptotic cell death 
was confirmed by AnxV/PI flow cytometry, defined by an increase of the PI-positive 
fraction (Fig. 2B). Cellular staining and immunoblot for autophagy were negative in 
response to IFN-β (Fig. 2C, D).  
We also assessed a possible modulation of spherogenicity of GIC by IFN-β. When 
exposed to 150 IU/ml IFN-β, singularized GIC cultures showed a reduced sphere 
formation at 1,000 – 10,000 cells per well; lower cell numbers did not result in 
efficient sphere formation, independent of IFN-β exposure (Fig. 2E). Conversely, 
exposure of fully formed spheres to 150 IU/ml IFN-β led to sphere disaggregation, 
with lesser and significantly smaller spheres remaining after 2 weeks of culture, as 
assessed by sphere count and absorbance (Fig. 2F). The single cells detaching from 
the sphere were viable during the first days after sphere disaggregation, but 
underwent cell death after a week, as assessed by trypan blue assay (data not 
shown). 
To assess the possible impact of IFN-β on stem cell differentiation, we analysed GS-
2, 5, 7 and 9 cells for changes in the expression of different stem cell markers. GS-2 
and GS-9 cells expressed CD133, but expression remained unchanged after 
exposure to 150 IU/ml IFN-β for 48 h. GS-5 and GS-7 did not express CD133 (Fig. 
2G). Moreover, IFN-β-treated GS-2, GS-5 and GS-9 cells showed no changes of 
GFAP, nestin, β-III-Tubulin or CNPase staining (shown for GS-2) (Fig. 2H). 
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Requirement for IFNAR-1 and IFNAR-2 for IFN-β-mediated sensitization to 
irradiation and TMZ 
To verify the role of IFNAR-1 and IFNAR-2 for IFN-β-mediated signal transduction 
and sensitization to TMZ and irradiation, we silenced the expression of both 
receptors by siRNA. Efficacy of gene silencing was assessed by RT-PCR for IFNAR-
1, which could not be assessed by flow cytometry (Fig. 1), and by RT-PCR and flow 
cytometry for IFNAR-2 (Fig. 3A). In the setting of TMZ exposure (Fig. 3B) or 
irradiation (Fig. 3C), silencing of IFNAR-1 or -2 or both attenuated the sensitizing 
effect of IFN-β in LNT-229 cells and LN-18 cells, confirming a role for IFNAR-
mediated signal transduction pathways in the IFN-β-induced sensitization process. 
IFNAR-2 gene silencing alone did not abrogate the effect of IFN-β on TMZ activity to 
the same extent as IFNAR-1 gene silencing alone.  
 
Response to TMZ, irradiation and IFN in GIC lines 
Since GIC are proposed to be the major source of tumor relapse and resistance, we 
next focused on these models. All investigated GIC, except GS-9, expressed MGMT 
and were highly resistant to TMZ (Supplementary Note 1, Fig. S1). IFN-β had no 
major effect on cell density of LTL cells, but a significant concentration-dependent 
impact of IFN-β alone was observed in GIC cells (Fig. 4A), as expected from the data 
shown in Fig. 2F. To assess whether IFN-β also partially overcomes TMZ resistance 
of GIC, we pre-exposed the cells to increasing concentrations of IFN-β (Fig. 4B, left 
panel), or to 150 IU/ml IFN-β for increasing periods of time (Fig. 4B, right panel), prior 
to treatment with TMZ at EC50 concentrations. All investigated GIC lines showed 
sensitization to TMZ after pre-exposure to IFN-β. Sensitization was significant in all 
cell lines when treated at a concentration of 150 IU/ml and for an exposure time of 24 
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h. Exposure of GS-2 cells to IFN-β for 24 h before administration of TMZ induced a 
strong growth-inhibiting effect on the sphere cultures (Fig. 4C). IFN-β-treated cells 
showed a decrease in clonogenic survival exceeding 50% compared to TMZ only-
treated cells, and exhibited a progressive loss of the sphere structure (see also Fig. 
2D). Similar effects, albeit with less impressive disaggregation, were observed for 
GS-5, GS-7 and GS-9 spheres, where cooperative effects were most prominent 
when IFN-β was given with TMZ at approximately EC50 concentrations.  
In the setting of irradiation experiments, GIC cells were not more resistant than LTL, 
with GS-2 displaying the strongest radioresistance of the panel, and GS-5 the 
weakest, possibly because of the TP53 wild-type status of this cell line (29) (Fig. 4D). 
Pre-exposure to increasing concentrations of IFN-β followed by low dose irradiation 
at 1 Gy resulted at least in additive inhibition of clonogenic survival. Again, in the 
rather radioresistant GS-2, a significant impact of IFN-β alone was observed (Fig. 4E, 
left panel); preexposure to IFN-β before irradiation led to a reduction of cell density 
fulfilling criteria of synergy, with an additional reduction of cell density of almost 50% 
when exposed to 150 IU/ml of IFN-β. GS-5 and GS-7 displayed synergistic effects at 
150 IU/ml IFN-β; no synergy was determined in GS-9 (Fig. 4E). 
 
Gene expression analyses 
Microarray-based gene expression profiling demonstrated IFN-β-dependent 
significant differential regulation of 509 genes after 6 h of IFN-β treatment in all three 
glioma cells lines investigated. Gene expression profiling after 24 h revealed 
significant differential regulation of 522 genes. The combined analysis, comparing the 
6 h and 24 h data, resulted in an overlap of 132 differentially expressed genes upon 
exposure to IFN-β in all three cell lines. In addition to the statistical analysis, where 
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IFN-β treatment effects were studied globally across all three cell lines, the impact of 
IFN-β was assessed individually for every single cell line. Single analysis probe lists 
of all three cell lines were compared at 6 h and 24 h, respectively (Fig. S2), defining 
overlapping lists of regulated genes as well as lists of genes exclusively regulated in 
each individual cell line. Multiple transcripts known to be regulated by IFN-β were 
found, including STAT1, interferon regulatory factors (IRF) and Mx1 (MxA) (Table 
S1). Moreover, we noted that a number of genes predicted to promote apoptotic 
signaling were induced by IFN-β, (Table S1), with an overlap of 6 genes annotated to 
both gene groups. Submission of the differentially expressed IFN-regulated genes to 
the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) identified a 
single main cluster of genes with strong interaction profile (Fig. S3A). Submission of 
the differentially expressed apoptosis-related genes revealed 3 main clusters, one 
cluster involving tumor necrosis factor-related apoptosis-inducing ligand (TRAIL / 
TNFSF10)-interacting genes (yellow), one involving XIAP-associated factor 1 (XAF1)-
interacting genes (blue), both connected via a third cluster centered around STAT1 
(green) (Fig. S3B). Induction of TRAIL and XAF1 was confirmed by RT-PCR and 
immunoblot analysis (Fig. 5). As we had observed differential reaction of the LTL cell 
line LNT-229 and the GIC cell lines GS-2 and GS-9 in clonogenic growth assays after 
exposure to IFN-β alone, we performed a gene ontology (GO) analysis of the genes 
exclusively regulated (FC > 2) in LNT-229, or the GIC lines (Fig. S2, peripheral 
regions), and identified several down-regulated genes involved in proliferation and 
cell growth, as well as up-regulated genes involved in negative regulation of 
proliferation or cell cycle arrest (Table S2). Notably, more genes were regulated in 
the GIC lines, with 2 main clusters of negative regulators of proliferation interacting 
mainly through JUN (blue cluster) and IL-8, IL-6 and JAK2 (red cluster) (Fig. S3C). 
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Altered expression of apoptosis regulating genes does not mediate enhanced 
clonogenic cell death induced by TMZ or irradiation 
To define a role for altered expression of apoptotic machinery genes in the biological 
effects of IFN-β, we examined whether IFN-β alone or when combined with different 
death stimuli promoted caspase activation under the conditions that induced 
synergistic inhibition of clonogenic survival (Figure 4). As a positive control, we used 
MFL since we previously observed IFN-α-induced sensitization to CD95L although 
the mechanism remained unclear then (35). MFL, but neither IFN-β nor TMZ, 
induced the cleavage of caspases 8 or 3 or DEVD-amc-cleaving caspase activity 
(Fig. 6A, B, C). Similar results were obtained for irradiation assays (data not shown).  
Preexposure to IFN-β did not result in caspase processing in cells exposed to TMZ 
either. Cell death in the investigated settings was confirmed by trypan blue dye 
exclusion (Fig. 6D). Finally, we performed clonogenic cell death assays similar to 
those in Figure 4 in the absence or presence of the broad spectrum caspase 
inhibitor, zVAD-fmk, to explore whether caspase inhibition attenuated or abrogated 
the effects in clonogenic cell death assays of IFN-β or TMZ alone or in combination 
(Fig. 6E). These assays confirmed the absence of a role for caspases, either upon 
single agent exposure or combination. The biological activity of zVAD-fmk under 
these conditions was confirmed by the inhibition of death receptor-mediated 
apoptosis as previously reported (36). 
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DISCUSSION 
 
Even after the implementation of TMZ as the first active chemotherapeutic agent 
when combined with standard radiotherapy, glioblastomas remain a major challenge 
in the field of neuro-oncology as they often relapse early and follow an invariably fatal 
clinical course. The latter is also true for the subgroup of patients with MGMT 
promoter methylation who derive most benefit from TMZ (4, 6). Large efforts have 
been made to improve prognosis by investigating new agents, either at recurrence, 
but recently more often early in development already in the paradigm of concomitant 
and adjuvant TMZ plus radiotherapy (3, 37, 38). 
Here we asked whether the immune modulatory cytokine, IFN-β, acts on glioma LTL 
and GIC lines, and sensitizes for the anti-clonogenic effects of TMZ or irradiation. We 
detected the expression of IFNAR-1 and -2 mRNA in all glioma cells, making them a 
potential target for IFN-β (Fig. 1A). Although detection of IFNAR-1 protein turned out 
to be challenging and was possible by immunofluorescence microscopy only, but not 
by flow cytometry, the biological effects of IFNAR-1 gene silencing were prominent: 
siRNA-mediated knockdown of the single IFNAR-1 chain inhibited IFN-β-mediated 
sensitization (Fig. 3), thereby confirming its biological function. Silencing of the 
IFNAR-2 chain alone inhibited IFN-β signalling only to a moderate level whereas 
silencing of IFNAR-1 was additionally required to abort the intracellular signal 
cascade enough to lead to a highly significant reduction in inhibition of clonogenic 
survival after IFN-β exposure (Fig. 3B,C). This may be due to the fact that, whilst 
IFNAR-2 holds only ligand-binding capacities, IFNAR-1, mainly inducing the 
intracellular signalling cascades, has also been described to have weak ligand 
binding activity, too, and may interact with other proteins in the absence of IFNAR-2 
(39, 40). Alternatively, although both siRNA pools reduced receptor mRNA 
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expression to a similar extend (Fig. 3A), differential protein stability may account for 
different biological efficiency of gene silencing in these experiments. Responsiveness 
of the cells was assessed by monitoring the expression of target proteins of the IFN-β 
signaling pathways (Fig. 1D).  
STAT-3 has been shown to be involved in antiproliferative functions when induced by  
IFN-α/β in human Daudi cells (41) and, in glioma cells, may act as an IFN-β-induced 
tumor inhibitor through negative modulation of miR-21 (42). Conversely, there is also 
accumulating evidence that STAT-3 is a driver of the malignant phenotype of 
glioblastoma (43). In our study, STAT-3 was uniformly phosphorylated in both LTL 
and GIC cell lines shortly after exposure to IFN-β (Fig. 1C). Thus, the biological 
consequences of STAT-3 phosphorylation may be context-dependent and need to be 
interpreted in the natural course or the therapeutic setting in which they are 
observed.  
Since GIC cells cultured under sphere conditions are considered to be a more 
resistant subpopulation of glioma cells (44-46), we characterized cell cycle 
progression, cell death induction and sphere formation capacity of GIC in the 
presence of IFN-β. Similar to LTL, we observed a cell cycle arrest with a reduced G1 
phase and an increase of the sub-G1 population, reflecting a moderate increase in 
the necrotic fraction on AnxV/PI flow cytometry (Fig. 2A,B). Exposure of singularized 
cells isolated from sphere cultures to IFN-β led to reduced sphere formation; 
moreover, fully formed spheres exposed to IFN-β for 24 h disaggregated in the first 
days (Fig. 2E,F), and the cells underwent delayed cell death after more than a week 
as assessed by trypan blue dye exclusion (data not shown). This sphere disruption 
effect with delayed cell death induction appears to be a major effect of IFN-β on GIC 
survival and to play a more important role than early classical apoptotic pathways 
that were not shown to be activated in the first 48 h post exposure in AnxV/PI flow 
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cytometry. Accordingly, Affymetrix array data demonstrated up-regulation of several 
apoptosis-related genes (Table S1, Fig. S3B), but ZVAD-fmk-controlled clonogenicity 
assays or DEVD-amc-cleaving-assays did again not confirm an induction of classical 
caspase-determined apoptotic pathways (Fig. 6C,E). 
We demonstrated that IFN-β facilitated the loss of clonogenicity induced by the 
standard chemotherapeutic agent for glioblastoma, TMZ. Since a sensitizing 
mechanism mediated through MGMT and TP53 had been described (20), we 
assessed IFN-β effects on a panel of cells with a heterogeneous pattern of MGMT 
and TP53 status (Supplementary Note 2, Fig. S4A). In our experimental settings, 
neither TP53 nor the MGMT status was important for the sensitizing effects of IFN-β. 
Specifically, we did not observe an induction of TP53 expression in cells with TP53 
wild-type transcriptional activity (LNT-229) or a down-regulation of MGMT expression 
in MGMT-expressing cells (LN-18) (Supplementary Note 2, Fig. S4C,D), nor did we 
observe MGMT- or TP53-associated changes in clonogenic survival assays, where 
sensitization by IFN-β was achieved independent of MGMT or TP53 status 
(Supplementary Note 2, Fig. S4A,B). Finally, Affymetrix chip analyses did neither 
detect induction of TP53 nor down-regulation of MGMT in the cell line expressing the 
respective gene products (TP53: LNT-229, GS-2; MGMT: GS-2; data not shown). 
The sensitization in the presence of MGMT is particularly attractive in view of the 
urgent clinical need for novel strategies for the majority of glioblastoma patients with 
tumors without MGMT promoter methylation. Moreover, we confirmed that 
preexposure to IFN-β sensitized different LTL to the anti-clonogenic effects of single 
doses of irradiation, too (Fig. S4B), and that these effects were mediated by the 
known receptors of IFN-β, IFNAR-1 and IFNAR-2 (Fig. 3). 
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GIC lines, which were confirmed here to be highly resistant to TMZ due to MGMT 
expression, appeared to be a special target to IFN-β which impaired sphere formation 
when administered alone, in the absence of major cell death induction (Fig. 2).  
Accordingly, we observed a growth-inhibiting effect of IFN-β in GIC cultures even 
when applied as a single agent (Fig. 4A), even in MGMT-expressing and highly TMZ-
resistant models (Fig. 4B-E). These chemosensitizing effects of IFN-β were 
concentration- and time-dependent, with significant results assessed at a 
concentration of 150 IU/ml, and a 24 h application (Fig. 4B, E). Of note, the molecular 
pattern in GIC cells was also diverse with regard to TP53 status (29), confirming that 
TP53 is not a major mediator of IFN-β-induced sensitization in glioma cells. 
All glioma models investigated here were sensitized at concentrations of IFN-β 
reached in the serum in clinical settings following intravenous application, where 
ranges of over 1000 IU/ml were reported at doses of 18x106 IE i.v. in healthy 
volunteers (47-49). IFN-β has been applied intravenously before in several clinical 
studies and was shown to be well tolerated without significant side effects (50), 
making it an interesting candidate for adjuvant glioblastoma therapy, close to 
practice. Thus, the present laboratory evidence, together with the wealth of data on 
the safety and tolerability of IFN-β in patients with multiple sclerosis, justifies further 
clinical trials of IFN-β in combination with radiotherapy and TMZ in patients with 
newly diagnosed glioblastoma, specifically those patients suffering from MGMT-
unmethylated tumors. 
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Figure legends 
 
Fig. 1. IFNAR-1 and -2 expression and responsiveness to IFN-β in human LTL 
and GIC. A,B. The cells were assessed for expression of IFNAR-1 and IFNAR-2 
mRNA by PCR with GAPDH as control (A) and of protein by cell surface flow 
cytometry (B, left panel; representative profiles for K562 as a positive control and 
LNT-229, LN-18, LN-308, GS-2 and GS-9 GIC cells; black curve: isotype control; 
grey curve: IFNAR antibody), or immunofluorescence staining (B, right panel; MCF-7 
and K562 were used as control). C. Phosphorylation levels of STAT-3 in a 
concentration- (left) and time-dependent (right) manner, shown representatively for 
LNT-229 cells (upper row), and for GS-7 and GS-9 GIC in a time-dependent manner 
(lower row). D. Responsiveness to IFN-β was assessed through detection of MxA 
protein in a concentration- (upper row) and time-dependent (lower row) manner, 
shown representatively for LNT-229 cells.  
 
Fig. 2. Assessment of IFN-β effects on GIC cells. A,B. LTL or GIC cells were 
exposed to IFN-β at 150 IU/ml for 24 h, cultured for an additional 48 h in serum-
enriched medium, and flow cytometric cell cycle analysis (A) or AnxV/PI flow 
cytometry (B) were performed. Cell distributions are shown as bar graphs (striped: 
sub-G1, black: G1, white: S, grey: G2/M). Cell lines in B match those shown in A 
above. C. LNT-229 or GS-2 cells were exposed to IFN-β (150 IU/ml), ddH2O aqua 
(negative control) or salinomycin (SAL) (4 µM) (positive control) for 24 h. D. LNT-229 
and GS-2 cells were treated as in C for protein lysates and assessed for LC3 A/B 
cleavage. GAPDH was used as control. E. The effect of IFN-β (150 IU/ml, 24 h) on 
sphere formation over a range of 5 – 10,000 single cells was assessed by sphere 
count and is shown for GS-2 (black square, IFN-β; white diamond, vehicle). Data are 
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expressed as mean ± SEM (n=6) (***p<0.001). Photomicrographs corresponding to 
1,000, 5,000 and 10,000 cells at 150 IU/ml IFN-β or control are included (original 
magnification x 40). F. The impact of IFN-β (150 IU/ml, 24 h exposure) on 
established sphere cultures was assessed after a period of 10 days (upper diagram). 
Composite quantification of the sphere number and size after exposure to IFN-β  150 
IU/ml for 24 h was performed by MTT absorbance measurement as a surrogate 
marker (lower diagram). Data are expressed as mean ± SEM (n=3) (***p<0.001). GS-
2 sphere cells were visualized by bright field microscopy with (right) or without (left) 
IFN-β exposure for 24 h (original magnification x 40). G, H. GS cells were exposed to 
ddH2O or IFN-β at 150 IU/ml for 48 h and assessed for the expression of stem cell 
markers by flow cytometry (black curve: isotype control; grey curve: specific antibody; 
SFI values displayed in the diagram) or immunostaining (left, ddH20 control; right, 
IFN-β exposure; insert, isotype control; Scale bars = 100 µm).  
 
Fig. 3. Abrogation of the sensitizing effect of IFN-β by IFNAR gene silencing. A. 
Gene silencing was performed by siRNA and confirmed by quantitative RT-PCR for 
IFNAR-1 and IFNAR-2 (left), and by flow cytometry for IFNAR-2 (right). B. Control-
transfected LNT-229 or LN-18 cells, siIFNAR-1-, siIFNAR-2-, or double-knockdown 
cells were exposed to IFN-β at 150 IU/ml and to TMZ in the respective EC50 
concentration range for 24 h each, at 48 h post transfection. Cell density was 
assessed by crystal violet staining after 2 weeks. Sensitizing effect of IFN-β is 
represented as delta of IFN-β-exposed versus vehicle-exposed cells. C. Control-
transfected, siIFNAR-1-, siIFNAR-2-, or double-knockdown LNT-229 (left) or LN-18 
(right) cells were exposed to IFN-β at 150 IU/ml at 48 h post transfection, irradiated 
with 5 Gy and allowed to grow for 2 weeks after after irradiation. The sensitizing 
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effect of IFN-β is represented as delta of IFN-β-exposed versus vehicle-exposed 
cells. 
 
Fig. 4. GIC sensitization to TMZ and irradiation by IFN-β 
A. LTL or GIC cells were exposed to IFN-β in a concentration-dependent manner and 
clonogenic survival was assessed by crystal violet (LTL) or MTT (GIC) assay. B. LTL 
or GIC cells were exposed to IFN-β in a concentration-dependent (left) or time-
dependent (right) manner before a 24 h pulse of TMZ in an EC50 concentration 
range. Clonogenic survival was assessed by crystal violet or MTT assay. C. GS-2, 
GS-5, GS-7 or GS-9 cells pre-exposed to IFN-β (150 IU/ml, 24 h) were treated with 
TMZ as shown in Fig. 3A and allowed to grow in neurobasal medium for 2 weeks 
before the assessment of clonogenicity by MTT assay (control: white bar; IFN-β: 
black bar). Data are expressed as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001, for 
the effect of IFN-β + TMZ versus TMZ alone). D. GS-2, GS-5, GS-7 or GS-9 cells 
were irradiated at 1, 3 or 5 Gy and monitored for clonogenic survival. Cell density 
was assessed by MTT assay after 2 weeks. E. GS-2, GS-5, GS-7 or GS-9 cells were 
pre-exposed to increasing concentrations of IFN-β for 24 h and subjected to 
irradiation with 1 Gy. Cell density was assessed after 2 weeks of clonogenic growth 
in neurobasal medium by MTT assay. Data are expressed as mean ± SEM 
normalized to untreated cells (*p<0.05, **p<0.01, ***p<0.001, relative to non-
irradiated cells; +, synergistic values, defined as > 10% difference between observed 
and predicted effect). For A, B and D, data are expressed as mean ± SEM (n=3) 
(*p<0.05, **p<0.01, ***p<0.001) relative to untreated cells. 
 
Fig. 5. Gene clusters induced by IFN-β. The proapoptotic proteins XAF-1 and 
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TRAIL were assessed by RT-PCR for RNA and by immunoblot for protein at 6 h and 
24 h after exposure to IFN-β in increasing doses (time points as assessed by micro-
array profiling), in LNT-229 (left) and GS-2 (right). 
 
Fig. 6. Role of apoptosis-regulatory genes in IFN-β-induced sensitization.  
A, B. Immunoblots were performed after exposure of LNT-229 (left panel) or GS-2 
(right panel) to IFN-β for 6 h (upper row) or 24 h (lower row) and the levels of 
caspase 8 and 3 were assessed either for IFN-β exposure alone, TMZ alone, or in 
combination as described. MFL and STS were used as a positive control (MFL: 1 
µg/ml; STS: 1µM). C. DEVD-amc cleaving assays were performed after 6 h of 
exposure (shown for 2h fluorescence measurement). D. Cell death was assessed by 
trypan blue exclusion after 6 h of exposure to IFN-β at 150 or 300 IU/ml, IFN-β + 
TMZ (10 µM for LNT-229, 500 µM for GS-2), or MFL and STS as positive controls, as 
described in C; ddH2O was used as negative control (white bars, alive cells; black 
bars, dead cells; normalized to 100% cells). E. Clonogenic cell death assays were 
performed for LNT-229 and GS-2 and analyzed by crystal violet staining (for LNT-
229) or MTT assay (for GS-2) at d10 after exposure to either IFN-β or TMZ alone, or 
combinations at indicated concentrations, with or without ZVAD-fmk (15 µM). 
	  
